MedicalResearch.com Interview with:
[caption id="attachment_51168" align="alignleft" width="136"]
Prof. John McMurray[/caption]
Prof. John McMurray
Professor of Cardiology
Institute of Cardiovascular & Medical Sciences
University of Glasgow
MedicalResearch.com: What is the background for this study?
Response: SGLT2 inhibitors
prevent the development of heart failure (HF) in patients with type 2 diabetes (T2D) – can they be used to
treat patients with established heart failure? Also, although introduced as a glucose-lowering treatment for T2D, experimental evidence suggests these drugs may have non-glucose mediated benefits. So, might they be a treatment for HF even in patients without diabetes?
Dr. Verge[/caption]
Danilo Verge MD MBA
Vice President, CVRM Global Medical Affairs
AstraZeneca
MedicalResearch.com: What is the background for this study?
Response: Dapagliflozin, an SGLT2 inhibitor (sodium-glucose co-transporter 2), has been shown to improve glycemic control by decreasing glucose reabsorption in the kidneys and inducing urinary glucose clearance. SGLT2 inhibitors have also been shown to be effective in lowering albuminuria and stabilizing eGFR (estimated glomerular filtration rate). The effect of dapagliflozin on UACR (urine albumin-to-creatinine ratio) has been shown to vary among patients.
The objective of this post-hoc analysis, based on the pooled data from 11 randomized, placebo-controlled clinical trials, was to assess baseline characteristics and concurrent changes in cardiovascular (CV) risk markers associated with UACR response to dapagliflozin.